Primo Goes Global: Radioligand Theranostics Take the Stage at AACR on Campus

Events

Dr. Ya-Yao Huang, CEO of Primo Biotechnology, was invited to deliver a keynote lecture at the American Association for Cancer Research (AACR), one of the world’s leading organizations dedicated to cancer research.

Lecture Topic:
Molecular Imaging: Update on PET Imaging in Oncological Research
Dr. Huang will share innovative developments in radiopharmaceuticals and their clinical applications, with a special focus on advancements in Taiwan.

This invitation highlights that Primo is not only a pharmaceutical manufacturer but also an innovative biotech brand with forward-looking research vision and strong international engagement. We sincerely invite researchers, clinicians, and partners from around the world to join Primo in advancing precision oncology!

Primo will continue to work alongside the world’s leading research organizations, creating new opportunities in cancer diagnosis and therapy while showcasing Taiwan’s research capabilities on the global stage.

About Primo

Primo collaborates with both domestic and international partners to accelerate progress in precision oncology, leveraging its capabilities in drug development, clinical translation, and GMP manufacturing to support next-generation therapeutics. For more information, please follow Primo Biotech on Facebook and LinkedIn.